Global Cell Free Protein Synthesis Market is valued at US$ 265.9 Mn in 2023, and it is expected to reach US$ 457.1 Mn by 2031, with a CAGR of 7.2% during the forecast period of 2024-2031.
Global Cell Free Protein Synthesis Market is valued at US$ 265.9 Mn in 2023, and it is expected to reach US$ 457.1 Mn by 2031, with a CAGR of 7.2% during the forecast period of 2024-2031.
CFPS (Cell-free protein synthesis) is an innovative technology that enables fast and simultaneous protein expression, free from cell membrane limitations. Its adaptability and efficiency make it a promising avenue for future drug development. By tapping into cellular translation machinery, CFPS simplifies protein synthesis while maintaining high quality. Its benefits include time-saving processes, flexibility, and the ability to handle even challenging proteins.
In biotechnology, CFPS finds diverse applications, spanning from producing therapeutic and membrane proteins to aiding drug discovery. It simplifies structural and functional protein analysis, eliminating the need for complex cell manipulation steps. CFPS comes in various formats, such as the PURE system and different batch and continuous flow methods, offering options tailored to specific needs. This versatility promises a straightforward path towards more efficient and cost-effective protein production for pharmaceuticals and other biotech products.
Download Free Report Sample Pages: https://www.insightaceanalytic.com/request-sample/1445
Recent Developments:
- In March 2024, Tierra Biosciences, a leader in using smart technology for making proteins, just got $11.4 million in funding. Big investors like Material Impact and Prosus Ventures are supporting them. This money will help Tierra make their protein-making technology even better, bringing new advances to biotech and protein science.
- In May 2024, Thermo Fisher Scientific finalized its acquisition of data intelligence firm CorEvitas for $912.5 million in cash. This acquisition, first announced on July 6th, will see CorEvitas become part of Thermo Fisher's Laboratory Products and Biopharma Services segment. CorEvitas, based in the US, offers real-world evidence solutions to pharmaceutical and biotech companies, collecting data from over 400 investigator sites and 100,000 patients. With 12 registries under its management, including nine autoimmune and inflammatory syndicated registries, CorEvitas is projected to generate $110 million in revenue by 2023.
List of Prominent Players in the Cell Free Protein Synthesis Market:
- Sutro Biopharma, Inc.
- Promega Corporation
- Thermo Fisher Scientific
- Takara Bio Inc.
- CellFree Sciences Co., Ltd.
- Merck KGaA
- New England Biolabs
- Jena Biosciences GmbH
- BioCentury Inc.
- Biotechrabbit GmbH
- Cube Biotech GmbH
- GeneCopoeia, Inc.
- Other Prominent Players
Market Dynamics:
Drivers:
The demand for therapeutic proteins is on the rise due to the escalating prevalence of chronic diseases like cancer, multiple sclerosis, HIV, and anemia. This surge has spurred the adoption of protein biology, offering targeted treatments with fewer side effects. Concurrently, advancements in protein expression studies, particularly through Continuous-Exchange Cell-free (CECF) systems, have revolutionized production methods.
CECF not only extends reaction lifetime but also boosts protein yield compared to traditional batch reactions. This innovation facilitates shorter expression times and allows for structural modifications, meeting the need for specific protein sequences and structures. Additionally, cell-free protein synthesis (CFPS) circumvents the time-consuming processes of cloning and cell culture, enhancing adaptability for high-throughput applications and yielding higher overall outputs.
The synergy of increasing R&D investment in proteomics and genomics, coupled with the burgeoning prevalence of cancer and infectious disorders, further propels the cell-free protein synthesis market. Pharmaceutical and biotech companies are increasingly leveraging these technologies to drive innovation and meet the growing demand for novel biologic products.
Challenges:
The widespread adoption of cell-free protein synthesis (CFPS) is hindered by several challenges. Foremost among these is the inability of CFPS to facilitate post-translational modifications, limiting its utility in synthesizing specific human therapeutics. Nonetheless, considerable strides have been made to overcome this limitation. Another significant barrier is the high cost associated with CFPS technology, which restricts its accessibility to many companies and research institutions.
Addressing this issue necessitates the reduction of reagent costs, particularly those related to energy sources and nucleotides. Additionally, protein folding complexities pose a formidable challenge for current CFPS systems, impeding the production of properly folded, functional proteins. Overcoming these challenges is crucial for unlocking the full potential of CFPS in biopharmaceutical production.
Regional Trends:
The cell-free protein synthesis market exhibits distinct regional trends, with North America emerging as the dominant player and the Asia Pacific region showing promising growth prospects. In North America, the market's supremacy is fueled by the presence of robust synthetic biology R&D facilities, advanced tools supporting synthesis processes, and a growing prevalence of chronic diseases like cancer, which boosts the frequency of cell-free protein synthesis applications.
Key drivers include escalating demand for therapeutic proteins, enzymes, and research reagents, alongside advancements in proteomics and genomics studies. Conversely, the Asia Pacific region is poised for significant expansion, driven by increasing research investments in countries such as Japan and China, the evolution of new drug therapeutic technologies, and a burgeoning focus on cell-based research in academia and the biotech sector.
Segmentation of Cell Free Protein Synthesis Market-
Cell Free Protein Synthesis Market- By Product
- Accessories and Consumables
- Lysate Systems
- Coli Lysate
- Wheat Germ Extract Lysate
- Insect Cell Lysate
- Human Cell Lysate
- Rabbit Reticulocyte Lysate
- Other Lysate Systems
Cell Free Protein Synthesis Market- By Application
-
- Enzyme Engineering
- Protein Labeling
- Protein-Protein Interaction
- High Throughput Production
- Other Application
Cell Free Protein Synthesis Market- By End-user
-
- Pharmaceutical & Biotechnology Companies
- Academics & Research Institutes
- Others
Cell Free Protein Synthesis Market- By Region
North America-
- The US
- Canada
- Mexico
Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific-
- China
- Japan
- India
- South Korea
- Southeast Asia
- Rest of Asia Pacific
Latin America-
- Brazil
- Argentina
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
- Rest of the Middle East and Africa
Order the 180 Pages Detailed Report @ https://www.insightaceanalytic.com/buy-report/1445
Call: North America +1 551 226 6109 Email: diana.dsouza@insightaceanalytics.com